World Journal of Hepatology, Jan 2026

World Journal of Hepatology Jan - 2026

“Blood markers vs transient elastography for liver stiffness and steatosis in metabolic dysfunction-associated steatotic liver disease “

Read more at:

Post Delphi consensus 2023, MASLD era has opened a Pandora’s box of non biopsy research arenas

Oflate FDA is considering Liver stiffness measurement for drug trials on MASLD, Liver biopsy might not be a mandatory requirement in future.

Read more at:

In the current WJH study, In addition to conventional APRI&FIB4, We evaluated
Novel markers- investigate the diagnostic accuracy and correlation of blood-based parameters 
 
 neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and neutrophil percentage-to-albumin ratio (NPAR) with LSM and CAP values in metabolic dysfunction-associated steatotic liver disease (MASLD) patients.
 
(Dr. Amal Joseph, my JR carried out  the project &we had presented the data at European Association of Study of liver, Fatty liver Summit, Estoril, Portugal in Feb 2025)

 

Next
Signs Your Digestive System Is Not Healthy (And What Your Gut Is Trying to Tell You)
Social Networks
DLC - Digestive & Liver Care Clinic
Copyright © 2019 – All rights reserved – Comprehensive Liver Care Trust – C.L.C

WEBSITE DESIGN & DEVELOPMENT BY GREHASOFT